Dual Incretin
Review
Research edition
October 2026

An explainer for the curious patient

Two pathways.
Better questions.

What does “dual” actually mean? Which study supports that claim? And what changes when the product changes?

Start with the mechanism ↗
A concept, not a score
GIPreceptor
+
GLP-1receptor
TirzepatideOne medicine · two receptor targets

Receptor activity explains a mechanism.
Clinical studies investigate outcomes.

FDA mechanism source ↗
01 / Ask what

Before asking how much better,
ask what was actually compared.

Read the study explainer ↗
The explainer series

Follow the question.

View the complete series ↗
Mechanism01

What “dual incretin” means—and what it leaves unanswered

Two receptor targets describe how a medicine acts. They do not give a patient a treatment ranking.

Read the explainer
Study reading02

How to read a head-to-head tirzepatide study

A result becomes more useful when the population, comparator and limits travel with it.

Read the explainer
Product identity03

Ingredient, brand and preparation: three labels to keep separate

A familiar ingredient name cannot do all the work of identifying the medicine in an offer.

Read the explainer
Reading research04

The trial population belongs in the headline

A result becomes more useful when the people studied remain visible beside the percentage.

Read the explainer
Time & evidence05

Seventy-two weeks is a study horizon, not a lifetime promise

Separate the time a result was measured from the time a treatment may be used.

Read the explainer
Mechanism & products06

Dual action does not mean two prescriptions

Receptor activity describes how a medicine acts; it is not a recipe for combining treatments.

Read the explainer
Scientific article07

STEP Semaglutide Analysis: Digestive Symptoms, Duration, and Weight Loss

A post hoc analysis separates symptom frequency, event duration and treatment discontinuation from the question of whether gastrointestinal discomfort drives semaglutide’s weight effects.

Read the explainer
Scientific article08

Tirzepatide Weight Loss Without Nausea: What the SURMOUNT Symptom Analysis Shows

A post hoc analysis of four trials found substantial weight reduction with and without nausea, vomiting, or diarrhea. The strongest inference is about symptom necessity—not which incretin receptor caused the results.

Read the explainer
The access review

The medicine is one part.
The care is another.

Promotional #1

CoreAge Rx

Compounded semaglutide and tirzepatide

The useful question

Which preparation, pharmacy and purchase term does the proposed plan specify?

Examine the offer ↗
Promotional #2

SuperHealthy Rx

Bundled compounded-medication promotion

The useful question

Does the dated promotional page match the product and terms at checkout?

Examine the offer ↗
Promotional #3

Likeness Rx

Compounded GLP-1 plans with several payment terms

The useful question

What obligation sits behind the lowest displayed monthly equivalent?

Examine the offer ↗
Additional access route

Ro

Membership-based care with separate medication expense

The useful question

What is the complete cost once the exact prescribed product is known?

Examine the offer ↗
Additional access route

WeightWatchers Clinic

Clinical membership alongside behavior support

The useful question

Which part of the program is covered by membership, and which is a separate prescription cost?

Examine the offer ↗
Additional access route

LillyDirect

Manufacturer-related pharmacy access and independent care links

The useful question

Which part of the pathway is the manufacturer offering, and who is responsible for treatment?

Examine the offer ↗
Additional access route

Mochi Health

Clinical membership; branded and compounded options

The useful question

Which studied product, if any, supports the claim made for my proposed preparation?

Examine the offer ↗
Additional access route

Henry Meds

Bundled compounded medication programs

The useful question

How does the proposed compounded product differ from the product named in a cited trial?

Examine the offer ↗
Additional access route

Hers

Care membership; medication purchased separately

The useful question

Does the evidence cited on Hers describe the medicine or the platform’s own patients?

Examine the offer ↗
Additional access route

Form Health

Obesity clinician and registered dietitian care

The useful question

What evidence supports the proposed medicine, and what evidence concerns the care program?

Examine the offer ↗
Additional access route

Ondra Health

Compounded GLP-1 plans with pharmacy-specific terms

The useful question

Which pharmacy and term can serve my state, and what quarterly rate applies if I cancel a prepaid plan?

Examine the offer ↗
Additional access route

Fitish RX

Compounded injections with distinct oral and microdose programs

The useful question

What evidence supports my exact preparation, and what happens if I cancel the selected bundle or renewal?

Examine the offer ↗
Compare all twelve access routes ↗

Mechanism ≠ personal outcome.
Ingredient ≠ product approval.
Placement ≠ clinical evidence.

Why these distinctions matter ↗